Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors-Reference-Cited by-同舟云学术

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors

Published:2023-07-14 Issue:14 Volume:66 Page:9577-9591
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ważyńska Marta A.¹^ORCID,Butera Roberto²,Requesens Marta¹,Plat Annechien¹,Zarganes-Tzitzikas Tryfon³,Neochoritis Constantinos G.⁴^ORCID,Plewka Jacek⁵^ORCID,Skalniak Lukasz⁵,Kocik-Krol Justyna⁵⁶,Musielak Bogdan⁵,Magiera-Mularz Katarzyna⁵^ORCID,Rodriguez Ismael⁵⁶^ORCID,Blok Simon N.⁷^ORCID,de Bruyn Marco¹,Nijman Hans W.¹,Elsinga Philip H.⁷^ORCID,Holak Tad A.⁵^ORCID,Dömling Alexander²⁸^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

2. Department of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands

3. Centre for Medicines Discovery, Nuffield Department of Medicine, Alzheimer’s Research UK Oxford Drug Discovery Institute, NDM Research Building, Roosevelt Drive, OX3 7FZ Oxford, U.K.

4. Department of Chemistry, University of Crete, Voutes, 70013 Heraklion, Greece

5. Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland

6. Doctoral School of Exact and Natural Sciences, Jagiellonian University, Prof. St. Łojasiewicz St 11, 30-348 Krakow, Poland

7. Department of Nuclear Medicine and MolecularImaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands

8. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry and Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc 77900, Czech Republic

Funder

HORIZON EUROPE Widening participation and spreading excellence

European Regional Development Fund

Fundacja na rzecz Nauki Polskiej

KWF Kankerbestrijding

H2020 Spreading Excellence and Widening Participation

Narodowe Centrum Badan i Rozwoju

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00254

Reference42 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

3. European Medicines Agency. EMEA/H/C/003985─EPAR Product Information 2022. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf (accessed Sept 01, 2022).

4. Opdivo (nivolumab) price, Farmacotherapeutisch Kompas. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/n/nivolumab#kosten (accessed Sept 01, 2022).

5. Queva, C.; Morrow, M.; Hammond, S.; Alimzhanov, M.; Babcock, J.; Foltz, I.; Kang, J. S.; Sekirov, L.; Boyle, M.; Chodorge, M. Targeted binding agents against b7-h1. WO 2011066389 A1, 2011.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1;Journal of Medicinal Chemistry;2024-03-05

2. Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands;EJNMMI Radiopharmacy and Chemistry;2024-02-19

3. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma;Cancers;2024-01-19

4. Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches;Journal of Personalized Medicine;2024-01-04

5. Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic;Journal of Medicinal Chemistry;2023-12-18